Compare Danaher Corporation (DHR) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Freshworks Inc — how do they compare? Danaher Corporation trades at $220.03 (market cap $152.87B), while Freshworks Inc trades at $13.9 (market cap $3.56B). The key difference: Danaher Corporation is far larger — about 42.9× Freshworks Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Freshworks Inc for 39 Days on average.
| DHR | FRSH | |
|---|---|---|
Market Cap | $152.87B | $3.56B |
Volume | 5,228,698 | 9,066,454 |
Sector | Health | Technology |
52-Week High | $242.05 | $13.92 |
52-Week Low | $161.91 | $6.88 |
Typical Hold Time | 69 Days | 39 Days |
Enterprise Value | $175.08B | $2.93B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Freshworks (FRSH) trades at $13.92, up 2.35% today, with strong technical momentum and bullish moving averages. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, while valuation metrics show a P/E of 21.63 and P/S of 4.28. Recent developments include FedRAMP certification progress and leadership appointments.
The outlook appears positive with analyst consensus at $14.60 price target and 50% buy ratings. Key opportunities include AI monetization and enterprise growth, while risks involve competitive SaaS market pressure and the need to sustain recent profitability gains amid ongoing investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
